STING1 and neoplasm: In combination therapy utilizing cGAS‐STING‐targeted nanovaccines and checkpoint inhibitors, the latter function by counteracting the immunosuppressive conditions within the tumor microenvironment, thus reinvigorating T‐cell functionality to effectively identify and eliminate cancer cells.